Thomas A. Shea
Director of Finance/CFO at ImmunoMolecular Therapeutics, Inc.
Profile
Thomas A.
Shea is currently the Chief Operating Officer & Chief Financial Officer at ImmunoMolecular Therapeutics, Inc. He previously held positions as Principal at ImmuLogic Pharmaceutical Corp.
from 1987 to 1993, Chief Financial Officer at Cubist Pharmaceuticals LLC, Chief Financial Officer at Tolerx, Inc. from 2005 to 2011, Chief Financial Officer at Ebi Life Sciences, Inc. from 2013 to 2016, Chief Financial Officer & Treasurer at Neurovance, Inc., Chief Financial Officer at Albireo Ltd., Chief Financial Officer at Euthymics Bioscience, Inc. from 2011 to 2013, Chief Financial Officer at Zalicus, Inc., Chief Financial Officer at EPIRUS Biopharmaceuticals, Inc., Chief Financial Officer at ImmusanT, Inc., Chief Financial Officer, Treasurer & Senior VP at EPIRUS Biopharmaceuticals, Inc. from 2015 to 2016, and Chief Financial Officer & Treasurer at Albireo Pharma, Inc. in 2018.
He obtained an undergraduate degree from Babson College in 1981 and an MBA from Suffolk University in 1997.
Thomas A. Shea active positions
| Companies | Position | Start |
|---|---|---|
ImmunoMolecular Therapeutics, Inc.
 ImmunoMolecular Therapeutics, Inc. BiotechnologyHealth Technology ImmunoMolecular Therapeutics LLC develops and manufactures immuno-therapeutic drugs for autoimmune diseases. The firm offers oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. The company was founded by Steve Orndorff, Aaron Michels, and Peter Gottlieb in 2015 and is headquartered in Broomfield, CO. | Director of Finance/CFO | 2020-07-07 |
Former positions of Thomas A. Shea
| Companies | Position | End |
|---|---|---|
| ALBIREO PHARMA, INC. | Director of Finance/CFO | 2018-10-08 |
| EPIRUS BIOPHARMACEUTICALS, INC. | Director of Finance/CFO | 2016-06-29 |
Ebi Life Sciences, Inc.
 Ebi Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ebi Life Sciences, Inc. is a private company that specializes in researching and developing life sciences. The company is based in Cambridge, MA. | Director of Finance/CFO | 2016-05-31 |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Director of Finance/CFO | 2010-12-31 |
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Corporate Officer/Principal | 1992-12-31 |
Training of Thomas A. Shea
| Babson College | Undergraduate Degree |
| Suffolk University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 12 |
|---|---|
ImmuLogic Pharmaceutical Corp.
ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Ebi Life Sciences, Inc.
Ebi Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ebi Life Sciences, Inc. is a private company that specializes in researching and developing life sciences. The company is based in Cambridge, MA. | Commercial Services |
Neurovance, Inc.
 Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | Commercial Services |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Euthymics Bioscience, Inc.
 Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Commercial Services |
EPIRUS Biopharmaceuticals, Inc. /Old/
 EPIRUS Biopharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology EPIRUS Biopharmaceuticals, Inc. develops monoclonal antibodies. It offers pharmaceutical products. The company is headquartered in Boston, MA. | Health Technology |
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
ImmunoMolecular Therapeutics, Inc.
ImmunoMolecular Therapeutics, Inc. BiotechnologyHealth Technology ImmunoMolecular Therapeutics LLC develops and manufactures immuno-therapeutic drugs for autoimmune diseases. The firm offers oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. The company was founded by Steve Orndorff, Aaron Michels, and Peter Gottlieb in 2015 and is headquartered in Broomfield, CO. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Thomas A. Shea
